Home - Mesoblast Ltd
Mesoblast is using its proprietary mesenchymal lineage cell technology platform to develop and commercialize innovative allogeneic cellular medicines to treat complex inflammatory diseases resistant to conventional standard of care.
Aug 4, 2023 · Mesoblast intends to enroll adult patients at highest mortality risk with SR-aGVHD where existing therapy has not improved outcomes and 90-day survival remains as low as 20-30%. 1 Mesoblast has generated pilot data through its emergency IND program in adults showing a survival benefit with
Jul 23, 2024 · Mesoblast’s lead product candidate, Ryoncil ® (remestemcel-L), is an investigational therapy comprising culture expanded mesenchymal stromal cells derived from the bone marrow of an unrelated donor.
Overview - Mesoblast Ltd
Mesoblast is using its proprietary technology platform to develop and commercialize innovative allogeneic cellular medicines to treat complex diseases resistant to conventional standard of care and where inflammation plays a central role.
Mesenchymal Lineage Cells - Mesoblast Ltd
Mesoblast’s proprietary mesenchymal lineage adult stem cells (MLCs) are found in multiple tissues where they play vital roles in maintaining tissue health.
3 days ago · Mesoblast’s RYONCIL® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in children 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy.
Product Candidates Overview - Mesoblast Ltd
Mesoblast’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. Proprietary media formulations, advances in development of 3D bioreactor technology and automation are intended to …
Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medical needs.
ASX Announcements | Mesoblast
Mesoblast 2024 Full Year Financial Results Webcast: 21 August 2024: Class Action Resolution: 31 July 2024: Quarterly Activities/Appendix 4C Cash Flow Report: 23 July 2024: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L: 22 July 2024: Confirmatory Phase 3 Back Pain Trial Actively Enrols: 12 July 2024: Appendix 3Y for Philip Krause ...
Preliminary Final Report including Appendix 4E | Mesoblast
News Release. Preliminary Final Report including Appendix 4E. August 31, 2023 at 8:08 AM AEST. 9d61b6ab-8e07-4767-841f-c7bd25e9b880.pdf 4 MB. Investor Relations. At A Glance. Overview; Corporate Governance; Board of Directors; Management Team; Company Announcements. ASX Announcements; Share Price & Tools.